<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03995342</url>
  </required_header>
  <id_info>
    <org_study_id>KY20192015-F-1</org_study_id>
    <nct_id>NCT03995342</nct_id>
  </id_info>
  <brief_title>The Correlation and Intervention of Intestinal Flora and Frailty in the Elderly</brief_title>
  <official_title>The Correlation and Intervention of Intestinal Flora and Frailty in the Elderly</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aim to evaluate the improvement and correlation of soluble dietary fiber
      (prebiotics) in the frailty of elderly people by a randomized, double-blind,
      placebo-controlled clinical trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      100 healthy controls, 100 pre-frailty and 100 frailty elderly will be included. the healthy
      controls will be received no intervention. The pre-frailty will be randomized at a 1：1 ratio
      to receive prebiotics (inulin) or placebo (maltodextrin) . The degree of improvements and
      correlation in frailty will be evaluated three months later.Similarly,the frailty also will
      be randomized at a 1：1 ratio to receive prebiotics (inulin) or placebo (maltodextrin). The
      degree of improvements and correlation in frailty will be evaluated three months later.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of frailty</measure>
    <time_frame>3 months</time_frame>
    <description>Frailty will be diagnosed according to Fried criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diversity analysis of intestinal flora</measure>
    <time_frame>3 months</time_frame>
    <description>Change of diversity analysis of intestinal flora</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Frailty Syndrome</condition>
  <arm_group>
    <arm_group_label>exprimental: Inulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inulin 15 grams after dissolution by mouth， every morning for three months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active comparator: maltodextrin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (maltodextrin) 15grams after dissolution by mouth， every morning for three months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Inulin</intervention_name>
    <description>Inulin 15 grams after dissolution by mouth， every morning for three months.</description>
    <arm_group_label>exprimental: Inulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Maltodextrin</intervention_name>
    <description>Placebo (maltodextrin) 15g/d，Oral administration after dissolution15g/d，Oral administration after dissolution</description>
    <arm_group_label>Active comparator: maltodextrin</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥65 years;

          -  Can get up from a chair and walk 6 meters

          -  Clearly consciousness, able to read or use words to express and communicate without
             difficulty

          -  Agree and accept the study plan

        Exclusion Criteria:

          -  Acute and chronic inflammatory disease of the intestine within 3 months

          -  Use of antibiotics, probiotics, prebiotics or synthetics, laxatives or diarrhea
             medications, proton pump inhibitors or gastric motility drugs within 1 month

          -  Dementia

          -  mental illness or blindness

          -  acute infection

          -  cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wang xiao ming</last_name>
    <role>Study Chair</role>
    <affiliation>Director of geriatrics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Xijing Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 10, 2019</study_first_submitted>
  <study_first_submitted_qc>June 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2019</study_first_posted>
  <last_update_submitted>January 8, 2020</last_update_submitted>
  <last_update_submitted_qc>January 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xijing Hospital</investigator_affiliation>
    <investigator_full_name>Wang Xiaoming-1</investigator_full_name>
    <investigator_title>Director of geriatrics</investigator_title>
  </responsible_party>
  <keyword>frailty, flora</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Frailty</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We will not make individual participant data (IPD) available to other researchers in a few years.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

